Umeå University's logo

umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Visceral leishmaniasis clinical management in endemic districts of India, Nepal, and Bangladesh
Institute of Medicine, Tribhuvan University, Kathmandu 44168, Nepal.
Umeå universitet, Medicinska fakulteten, Institutionen för epidemiologi och global hälsa. KEM Hospital Research Center, Pune, Maharashtra 411011, India.
Rajendra Memorial Research Institute of Medical Sciences, Patna, Bihar 800007, India.
Rajendra Memorial Research Institute of Medical Sciences, Patna, Bihar 800007, India.
Vise andre og tillknytning
2012 (engelsk)Inngår i: Journal of Tropical Medicine, ISSN 1687-9686, E-ISSN 1687-9694, Vol. 2012, artikkel-id 126093Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: National VL Elimination Programs in India, Nepal and Bangladesh face challenges as home-based Miltefosine treatment is introduced. Objectives. To study constraints of VL management in endemic districts within context of national elimination programs before and after intervention.

Methods: Ninety-two and 41 newly diagnosed VL patients were interviewed for clinical and provider experience in 2009 before and in 2010 after intervention (district training and improved supply of diagnostics and drugs). Providers were assessed for adherence to treatment guidelines. Facilities and doctor-patient consultations were observed to assess quality of care.

Results: Miltefosine use increased from 33% to 59% except in Nepal where amphotericin was better available. Incorrect dosage and treatment interruptions were rare. Advice on potential side effects was uncommon but improved significantly in 2010. Physicians did not rule out pregnancy prior to starting Miltefosine. Fever measurement or spleen palpation was infrequently done in Bangladesh but improved after intervention (from 23% to 47%). Physician awareness of renal or liver toxicity as Miltefosine side effects was lower in Bangladesh. Bio-chemical monitoring was uncommon. Patient satisfaction with services remained low for ease of access or time provider spent with patient. Health facilities were better stocked with rK39 kits and Miltefosine in 2010. 

sted, utgiver, år, opplag, sider
Hindawi Publishing Corporation, 2012. Vol. 2012, artikkel-id 126093
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-200612DOI: 10.1155/2012/126093Scopus ID: 2-s2.0-84862291360OAI: oai:DiVA.org:umu-200612DiVA, id: diva2:1708100
Tilgjengelig fra: 2022-11-02 Laget: 2022-11-02 Sist oppdatert: 2022-11-02bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstScopus

Person

Hirve, Siddhivinayak

Søk i DiVA

Av forfatter/redaktør
Hirve, Siddhivinayak
Av organisasjonen
I samme tidsskrift
Journal of Tropical Medicine

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 16 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf